Anagrelide Remodels the PDE3A–SLFN12 Interactome to Associate with Translation Initiation Machinery in Cancer Cell Lines
Molecular & Cellular Proteomics · 2026-10 · 25 (10) · 101663
DOI: 10.1016/j.mcpro.2026.101663 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular & Cellular Proteomics, 2026-10. Verfasst von Sami Salmikangas und 9 weiteren Autor:innen. Beteiligte Einrichtung: Rare Cancers Research Group, Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. Electronic address:…. Hauptthemen laut MEDLINE: Cyclic Nucleotide Phosphodiesterases, Type 3, Peptide Chain Initiation, Translational. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sigrid Jusélius Foundation, Research Council of Finland, Medical Association of Life and Health.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Rare Cancers Research Group, Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. Electronic address: sami.salmikangas@helsinki.fi.
- Rare Cancers Research Group, Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
- Rare Cancers Research Group, Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Stem Cells and Metabolism Research Program, Faculty of Medicine, University of Helsinki,…
- Institute of Biotechnology, Helsinki Institute of Life Science HiLIFE, University of Helsinki, Helsinki, Finland.
- Rare Cancers Research Group, Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; HUS Diagnostic Center, Department of Pathology, University of Helsinki and Helsinki Unive…
- HUS Diagnostic Center, Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Förderung
- Sigrid Jusélius Foundation
- Research Council of Finland
- Medical Association of Life and Health
- Outpatient Research Foundation
- Relander Foundation sr
- Mary and Georg C Ehrnrooth Foundation
Zitieren
APA
Salmikangas, S., Lindholm, I., Sultana, N., Merikoski, N., Toivanen, K., Liu, X., Varjosalo, M., Böhling, T., Vesterinen, T., & Sihto, H. (2026). Anagrelide Remodels the PDE3A–SLFN12 Interactome to Associate with Translation Initiation Machinery in Cancer Cell Lines. Molecular & Cellular Proteomics, 25(10), 101663. https://doi.org/10.1016/j.mcpro.2026.101663
Vancouver
Salmikangas S, Lindholm I, Sultana N, Merikoski N, Toivanen K, Liu X, et al. Anagrelide Remodels the PDE3A–SLFN12 Interactome to Associate with Translation Initiation Machinery in Cancer Cell Lines. Molecular & Cellular Proteomics. 2026;25(10):101663. doi:10.1016/j.mcpro.2026.101663
BibTeX
@article{Salmikangas2026,
author = {Salmikangas, Sami and Lindholm, Iina and Sultana, Nasrin and Merikoski, Nanna and Toivanen, Kirsi and Liu, Xiaonan and Varjosalo, Markku and Böhling, Tom and Vesterinen, Tiina and Sihto, Harri},
title = {Anagrelide Remodels the PDE3A–SLFN12 Interactome to Associate with Translation Initiation Machinery in Cancer Cell Lines},
journal = {Molecular & Cellular Proteomics},
year = {2026},
volume = {25},
number = {10},
pages = {101663},
doi = {10.1016/j.mcpro.2026.101663}
}
EUVIMED